To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Cat. No.: TDLD-0825-LD76
M2pep Pep-LNP
M2pep Pep-LNP is a state-of-the-art peptide-functionalized lipid nanoparticle (LNP), designed for efficient targeted delivery of therapeutic cargoes such as siRNA, mRNA, DNA, small molecule drugs, and RNA-guided gene editing systems. Engineered with the M2pep peptide, this LNP specifically recognizes and binds to M2 macrophages, a key cell type in immune regulation and disease pathogenesis. The M2pep peptide, known for its multifaceted biological activities, facilitates interaction with these cells, potentially modulating their differentiation, proliferation, surface marker expression (like CD206 and CD163), and intracellular signaling pathways. Our LNP is prepared using Targeting Module and a variety of optional lipid formulations including DLin-MC3-DMA, LP-01, ALC-0315, SM102, and others. These formulations are carefully selected to ensure the LNP has uniform particle size, high encapsulation efficiency, stability, and targeted delivery. Applications of M2pep Pep-LNP include research into immunomodulatory therapies for cancers, chronic inflammatory diseases, and fibrosis, where targeting M2 macrophages holds significant therapeutic potential. Please note that this product is intended for research purposes only.
Inquiry
SPECIFIC INQUIRY
Clear AllInquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Creatibe Biolabs' custom LNP was the only solution that
successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high
efficiency and low toxicity.”
Dr. Evelyn Reed
Postdoctoral Researcher, Leading
University
Our siRNA candidate was failing due to off-target toxicity, but
Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our
preclinical program.”
Ben Carter
Project Manager
Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform
was the key to unlocking our candidate's full therapeutic potential.”
Dr. Kenji Tanaka
Principal Scientist, Large
Pharma Corp
Our oncology drug's efficacy was limited by poor tumor
accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting
we needed, dramatically increasing the drug's therapeutic index.”
Dr. Clara Schmidt
Senior Scientist, Oncology
Innovations Inc.
We required a delivery system that would only release its payload
in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed
flawlessly, minimizing systemic exposure.”
David Chen
Formulation Scientist
Outstanding expertise in antibody engineering.The team's attention
to detail and innovative approaches have sianificantly accelerated our development timeline.
